Pfizer, Celltrion present data on Inflectra at 12th ECCO Congress

Pfizer is in the midst of an ongoing 54-week study of Inflectra.
Pfizer is in the midst of an ongoing 54-week study of Inflectra. | File photo

Pfizer Inc. and Celltrion Healthcare presented data at the 12th Congress of the European Chron’s and Colitis Organisation showing Inflectra (infliximab CT-P13) delivers similar efficacy and safety as Remicade (infliximab) for treating Chron’s Disease.

“Today’s presentation of randomized control trial data in patients with Crohn’s disease further supports the existing clinical profile of CT-P13 in inflammatory bowel disease. In addition to existing data from the registration studies, real-world experience and the NOR-SWITCH trial, this data adds to the body of evidence supporting use of CT-P13 across its approved indications,” Pfizer Essential Health Chief Medical Officer Dr. Sam Azoulay said in a statement.

Pfizer is in the midst of an ongoing 54-week study of Inflectra’s longer-term safety and efficacy and additional results are expected this year. 

The company noted in a press release that the study is also examining the treatment response and safety profile in patients who switch from Remicade to Inflectra, as well as patients who switch from Inflectra to Remicade.

Want to get notified whenever we write about Pfizer ?
Next time we write about Pfizer, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Pfizer 235 E 42nd St New York, NY 10017-5703